Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels.

Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1 Jan 1999Cited by 68 (Europe PMC)

PMID10550446DOI10.1007/s001980050151PepBankPUB-10550446

Publisher page PubMedAsk about this study

Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, serum 25(OH) vitamin D decreased in each hPTH group.
In plain wordsIn osteoporosis patients, blood 25(OH) vitamin D decreased from baseline in each hPTH group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum 25(OH) vitamin D
Study
n = 220
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50, 100 or 200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum 25(OH) vitamin D and 1,25(OH)(2) vitamin D decreased in each group at the 48th week (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044610
02HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, serum 1,25(OH)(2) vitamin D decreased in each hPTH group.
In plain wordsIn osteoporosis patients, blood active vitamin D decreased from baseline in each hPTH group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum 1,25(OH)(2) vitamin D
Study
n = 220
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50, 100 or 200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum 25(OH) vitamin D and 1,25(OH)(2) vitamin D decreased in each group at the 48th week (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044611
03HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, urinary hydroxyproline declined significantly in each hPTH group.
In plain wordsIn osteoporosis patients, urine hydroxyproline decreased from baseline in each hPTH group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary hydroxyproline
Study
n = 220
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50, 100 or 200 units weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Urinary hydroxyproline, pyridinoline and deoxypyridinoline declined significantly in each group.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044614
04HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, urinary pyridinoline declined significantly in each hPTH group.
In plain wordsIn osteoporosis patients, urine pyridinoline decreased from baseline in each hPTH group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary pyridinoline
Study
n = 220
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50, 100 or 200 units weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Urinary hydroxyproline, pyridinoline and deoxypyridinoline declined significantly in each group.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044615
05HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, urinary deoxypyridinoline declined significantly in each hPTH group.
In plain wordsIn osteoporosis patients, urine deoxypyridinoline decreased from baseline in each hPTH group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary deoxypyridinoline
Study
n = 220
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50, 100 or 200 units weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Urinary hydroxyproline, pyridinoline and deoxypyridinoline declined significantly in each group.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044616
06HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, backache improved in a proportion of each hPTH group.
In plain wordsIn osteoporosis patients, back pain improved from baseline in some patients in each hPTH group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBackache improvement
Study
n = 220
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Studied dose
50, 100 or 200 units weekly · subcutaneousAs given in this study (human).
Measurements
Backache improvement
30 to 40%
each group
Source sentences
Summary
Backache improved in 30-40% of each group.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044617
07HumanRandomized controlled trialSafety outcome
In osteoporosis patients receiving weekly hPTH, no serious adverse effects were found during the study.
In plain wordsIn osteoporosis patients receiving weekly hPTH, researchers found no serious adverse effects.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerious adverse effects
Study
n = 220
Outcome group
Adverse events · Whole body
Studied dose
50, 100 or 200 units weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
No serious adverse effects were found during the test period.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044618
08HumanRandomized controlled trialEfficacy outcome
In patients with osteoporosis, lumbar spine BMD rose by 0.6% after 48 weeks in the low-dose hPTH group, less than in the medium and high groups.
In plain wordsIn osteoporosis patients, spine bone density rose 0.6% with low-dose hPTH, less than with higher doses.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD, L
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Measurements
BMD change
0.6%
L at 48 weeks
Source sentences
Summary
Lumbar spine bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) increased by 0.6%, 3.6% and 8.1% after 48 weeks in groups L, M and H respectively, responses in groups M and H being significantly higher than in L (p<0.05, Mann-Whitney U-test).
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044601
09HumanRandomized controlled trialEfficacy outcome
In patients with osteoporosis, medium-dose hPTH increased lumbar spine BMD more than low-dose hPTH.
In plain wordsIn osteoporosis patients, medium-dose hPTH increased spine bone density more than low-dose hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD, M
Study
n: not reported in source
Comparator
50 units weekly
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Measurements
BMD change
3.6%
M at 48 weeks
BMD change
0.6%
L at 48 weeks (comparator)
Source sentences
Summary
Lumbar spine bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) increased by 0.6%, 3.6% and 8.1% after 48 weeks in groups L, M and H respectively, responses in groups M and H being significantly higher than in L (p<0.05, Mann-Whitney U-test).
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044602
10HumanRandomized controlled trialEfficacy outcome
In patients with osteoporosis, high-dose hPTH increased lumbar spine BMD more than low-dose hPTH.
In plain wordsIn osteoporosis patients, high-dose hPTH increased spine bone density more than low-dose hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD, H
Study
n: not reported in source
Comparator
50 units weekly
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Measurements
BMD change
8.1%
H at 48 weeks
BMD change
0.6%
L at 48 weeks (comparator)
Source sentences
Summary
Lumbar spine bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) increased by 0.6%, 3.6% and 8.1% after 48 weeks in groups L, M and H respectively, responses in groups M and H being significantly higher than in L (p<0.05, Mann-Whitney U-test).
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044603
11HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients receiving hPTH, metacarpal BMD did not change significantly.
In plain wordsIn osteoporosis patients receiving hPTH, hand bone density did not change significantly from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMetacarpal BMD
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50, 100 or 200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Metacarpal BMD and cortical thickness measured by radiogrammetry did not change significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044604
12HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients receiving hPTH, cortical thickness did not change significantly.
In plain wordsIn osteoporosis patients receiving hPTH, cortical bone thickness did not change significantly from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical thickness
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50, 100 or 200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Metacarpal BMD and cortical thickness measured by radiogrammetry did not change significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044605
13HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, serum calcium decreased in each hPTH dose group.
In plain wordsIn osteoporosis patients, blood calcium decreased from baseline in each hPTH dose group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum calcium
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
50, 100 or 200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum calcium decreased in each group and serum phosphorus decreased in groups M and H.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044606
14HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, serum phosphorus decreased in the medium- and high-dose hPTH groups.
In plain wordsIn osteoporosis patients, blood phosphorus decreased from baseline with medium- and high-dose hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphorus
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
100 or 200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum calcium decreased in each group and serum phosphorus decreased in groups M and H.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044607
15HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, urinary calcium/creatinine decreased at week 12 in the group given 200 units of hPTH (1-34) weekly.
In plain wordsIn osteoporosis patients, urine calcium/creatinine decreased at week 12 with the highest weekly hPTH dose.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary calcium/creatinine, H
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
200 units weekly · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Urinary calcium/creatinine decreased at the 12th week in group H and at the 24th and 48th weeks in groups M and L.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044608
16HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, urinary calcium/creatinine decreased at weeks 24 and 48 in the groups given 100 or 50 units of hPTH (1-34) weekly.
In plain wordsIn osteoporosis patients, urine calcium/creatinine decreased at weeks 24 and 48 with the medium and low weekly hPTH doses.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary calcium/creatinine, M and L
Study
n: not reported in source
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
50 or 100 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Urinary calcium/creatinine decreased at the 12th week in group H and at the 24th and 48th weeks in groups M and L.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044609
17HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, bone-type alkaline phosphatase increased early in the medium- and high-dose hPTH groups.
In plain wordsIn osteoporosis patients, a bone formation marker increased from baseline early with medium- and high-dose hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone alkaline phosphatase, early
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 or 200 units weekly · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
Serum bone-type alkaline phosphatase was increased at the fourth week in groups H and M and decreased at the 48th week in group H.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044612
18HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, bone-type alkaline phosphatase decreased late in the high-dose hPTH group.
In plain wordsIn osteoporosis patients, a bone formation marker decreased from baseline late with high-dose hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone alkaline phosphatase, late
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 units weekly · subcutaneous · 48 weeksAs given in this study (human).
Source sentences
Summary
Serum bone-type alkaline phosphatase was increased at the fourth week in groups H and M and decreased at the 48th week in group H.
1 context sentence(design, population, supporting numbers)
Summary · context
weekly subcutaneous injection of 50 units (L group), 100 units (M group) or 200 units (H group) of hPTH (1-34) was started in 220 patients with osteoporosis at 71 institutions randomly divided into three groups in a double-masked system.
Report a problemFND-1055044613

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.